Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma

Inclusion Criteria:

• Physician-diagnosed mild-to-moderate asthma for more than 12 months based on GINAguidelines.

• At least 1 asthma exacerbation in the year prior to Screening (Visit 1).

• Pre-BD FEV1 of equal or more than 40% of predicted normal (by Global Lung FunctionInitiative [GLI] standards) at Screening (Visit 1).

Exclusion Criteria:

Participants are excluded from the study if any of the following criteria apply:

• Other severe lung diseases (eg, chronic obstructive pulmonary disease [COPD].bronchiectasis, idiopathic pulmonary fibrosis, etc) which may impair lung function.

• Participants who experience a deterioration of asthma that results in emergencytreatment or hospitalization, or treatment with systemic steroids within 1 monthprior to the Screening (Visit 1) (counting from the date of completion of treatmentfor asthma exacerbation).

• Participants who have experienced an upper or lower respiratory tract infectionwithin the 4 weeks prior to Screening (Visit 1).

• Known history of, or suspected, significant current immunosuppression, includinghistory of invasive opportunistic or helminthic infections despite infectionresolution or otherwise recurrent infections of abnormal frequency or prolongedduration.

• Evidence of any infection requiring systemic anti-infective treatment within 2 weeksbefore Screening (Visit 1) or during the screening period. Significant viralinfections within 2 weeks before Screening (Visit 1) or during the screening periodeven if the participant has not received systemic antiviral treatment (eg, influenzareceiving only symptomatic treatment).

• Participants with active tuberculosis (TB), latent TB, a history of incompletelytreated TB, suspected extrapulmonary TB infection, or who are at high risk ofcontracting TB (such as close contact with individuals with active TB), or receivedBacillus Calmette-Guérin (BCG)-vaccination within 12 weeks prior to Screening (Visit 1).

• Severe concomitant illness that would in the Investigator's opinion inhibit theparticipant's participation in the study, including for example, but not limited to,hypertension, renal disease, neurological conditions, heart failure, and pulmonarydisease.

NOTE: The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical study.